Founded last year, the company plans to develop mass spec-based tests to protein isoforms using a workflow that eliminates both LC and protein digestion.

Improved data capture is expected to help TriCore further develop the analytics that are the basis for the Lab 2.0 model it advocates.

The company is confident about bringing the test to market despite potential future competition and views it as an easy fit for its existing sales channels.

The firm anticipates that the award will accelerate the development of its over-the-counter and professional-use influenza and multiplex respiratory pathogen tests. 

According to the company, the designation will help speed potential FDA approval of the test, which uses Ceres' Nanotrap technology to diagnose Lyme disease.